QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances Kilogram-Scale Manufacturing for ONC010 Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in the development of ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. Conducted through its chemistry, manufacturing and controls collaboration with Dalton Pharma Services, the effort resulted in the production and isolation of approximately 952 grams of B4 material, supporting future formulation development, GMP production and planned clinical studies. The company said the manufacturing milestone strengthens its integrated development strategy and supports the establishment of a scalable production…